Q&A: Behind the approvals—decades of research lead to a new generation of targeted cancer therapies
Last month, the U.S. Food and Drug Administration (FDA) approved the use of the drug capivasertib, in combination with a current cancer treatment called fulvestrant for patients with the most common type of breast cancer, ...
Dec 21, 2023
0
0